Fig. 5.

Individual response of three exemplary ccRCC lines to treatment with tyrosine kinase inhibitors. The cell lines of all tumor entities displayed different responses to the treatment with tyrosine kinase inhibitors in the CellTiter-Glo assay. CcRCC17 belonged to a patient who was diagnosed with primary metastatic disease and underwent neo-adjuvant treatment with sunitinib and nivolumab before nephrectomy, showing in vitro therapy response especially to axitinib and cabozantinib; ccRCC clear cell renal cell carcinoma